11.2 Capital

11.2 Capital

A venture capital and private equity firm focused on emerging technologies in artificial intelligence, cybersecurity, robotics, quantum, new space, computational therapeutics and synthetic biology.

11.2 Capital is a venture capital and private equity firm focused on emerging technologies in artificial intelligence, cybersecurity, robotics, quantum, new space, computational therapeutics and synthetic biology that is headquartered in San Francisco, California and was founded in 2014 by Shelley Zhuang. The firm specializes in offering its early stage companies several services such as technical recruiting, partnerships, customer introductions, and follow-on financing.

Notable investments made by 11.2 Capital include: TigerGraph, WhiteOps, Avaamo, Ginkgo Bioworks, Forter, Aunransa, Bay Labs, Cruise, Vertical, Notable Labs, Savioke, Molecular Assemblies, Kindred, Deep Genomics, and Lucira Health.

Timeline

2014
11.2 Capital was founded by Shelley Zhuang.

Funded Companies

Company
Description
Industry
Website
Location
Synthace

Synthace is a software company based out of London, UK building automation software that gives biologists the ability to control and analyze the performance of lab hardware.

A company that allows developers build mobile AR applications, save and share AR content in physical spaces.

Lucira Health is a company developing and producing health diagnostic hardware that transforms a smartphone into a portable and real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids.

Passage AI is a Mountain View, Contra Costa County, California-based artificial intelligence company.

9 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.